Over The Counter Pain Medication Market to Surpass $35.50 Billion by 2031, Says Coherent Market Insights (CMI)
19 sept. 2024 11h08 HE
|
CMI
Burlingame, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The global Over The Counter Pain Medication Market Size to Grow from USD 27.12 Billion in 2024 to USD 35.50 Billion by 2031, at a Compound Annual...
Third Annual Hiking Event Brings Awareness to Chronic Pain in Canadian Veterans
26 août 2024 10h57 HE
|
Chronic Pain Centre of Excellence for Canadian Veterans
HAMILTON, Ontario, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Nine Canadian military Veterans living with chronic pain from across Canada completed the third annual Military Veterans Alpine Challenge (Alpine...
PAINWeek Heads to Las Vegas, September 3-6, as the Largest and Most Innovative Pain Management Conference for Frontline Healthcare Professionals
31 juil. 2024 11h00 HE
|
PAINWeek
Boca Raton, FL, July 31, 2024 (GLOBE NEWSWIRE) -- Building on the momentum of a record-breaking year, PAINWeek, produced by Informa Connect, unveils details of the 18th annual conference. This year,...
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
25 juil. 2024 08h30 HE
|
FN Media Group LLC
PALM BEACH, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The fibromyalgia treatment market has witnessed positive growth trends over the past few years. There is higher...
Curonix Receives the First Full-Body Peripheral Nerve Stimulator (PNS) FDA Clearance, including Craniofacial Pain Indication, for its Freedom® PNS System
09 juil. 2024 08h00 HE
|
Curonix LLC
Curonix Receives the First Full-Body Peripheral Nerve Stimulator (PNS) FDA Clearance, including Craniofacial Pain Indication, for its Freedom® PNS System.
Opioids Market to Soar to USD 29.5 Billion by 2033 | Driven by Chronic Pain Prevalence and Increasing Surgical Procedures
13 févr. 2024 07h23 HE
|
Market.Us
New York, Feb. 13, 2024 (GLOBE NEWSWIRE) -- According to Market.us, the Global Opioids Market size is projected to exceed USD 29.5 Billion by 2033, with a promising CAGR of 2.9% from 2024 to 2033. ...
Chronic Pain Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Key Players - Paradigm Biopharmaceuticals, Noven Pharmaceuticals, Pfizer, Biogen, Tonix Pharmaceuticals, Amzell, Bayer, and Others
07 févr. 2024 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Chronic Pain Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Key Players - Paradigm Biopharmaceuticals, Noven...
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
01 févr. 2024 10h00 HE
|
Silo Pharma, Inc.
Preparing Pre-Investigational New Drug Application for lead drug program SPC-15 Company plans to pursue FDA streamlined 505(b)(2) pathway for clinical drug development SARASOTA, FL, Feb. 01,...
Fibromyalgia Treatment Market Projected to Surpass US$ 2.7 Billion in Revenue by 2033, According to Persistence Market Research
18 janv. 2024 09h45 HE
|
Persistence Market Research
New York, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Market Overview: The global revenue from the fibromyalgia treatment market stands at US$ 1.3 billion in 2022, with the global market expected to grow...
Curonix Partners with Sure Med Compliance to Expand PNS Clinical Evidence
18 janv. 2024 08h00 HE
|
Curonix LLC
Curonix Partners with Sure Med Compliance to Expand PNS Clinical Evidence